Quist, Sara (2019) Cost-effectiveness analysis of pembrolizumab as first- or second-line treatment for stage III and IV melanoma in the Netherlands. Bachelor's Project, Pharmacy.
![[img]](https://fse.studenttheses.ub.rug.nl/style/images/fileicons/text.png) |
Text
bPHAR_2019_QuistSW.pdf Restricted to Registered users only Download (1MB) |
Abstract
De begeleider en/of auteur heeft geen toestemming gegeven tot het openbaar maken van de scriptie. The supervisor and/or the author did not authorize public publication of the thesis.
| Item Type: | Thesis (Bachelor's Project) |
|---|---|
| Supervisor name: | Postma, M.J. |
| Degree programme: | Pharmacy |
| Thesis type: | Bachelor's Project |
| Language: | English |
| Date Deposited: | 03 Jul 2019 |
| Last Modified: | 03 Jul 2019 11:41 |
| URI: | https://fse.studenttheses.ub.rug.nl/id/eprint/19825 |
Actions (login required)
 |
View Item |